Downregulation of human intercellular adhesion molecule-1 attenuates the metastatic ability in human breast cancer cell lines

DALIN DI1, LEI CHEN2, LINA WANG1, PING SUN1, YANFEI LI1, ZHIWEI XU1 and JIYU JU1

1Department of Immunology, Weifang Medical University; 2Department of Hematology, Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261053, P.R. China

Received September 30, 2015; Accepted December 9, 2015

DOI: 10.3892/or.2016.4543

Abstract. Intercellular adhesion molecule-1 (ICAM-1) is a cell surface glycoprotein that belongs to immunoglobulin superfamily and plays an important role in tumor cell expansion or metastasis. However, the detailed mechanisms of ICAM-1 in breast cancer remain unclear. In this study, we evaluated the expression level of ICAM-1 in breast cancer using tissue microarray and clinical tissue specimens by immunohistochemical method, and the results revealed that ICAM-1 is highly expressed in the breast cancer tissues. To investigate whether ICAM-1 can affect the metastasis ability in breast cancer, we knocked down ICAM-1 expression in breast cancer cell line MCF-7 by using lentivirus-mediated RNA interference (RNAi). As a result, we stably silenced ICAM-1 expression in breast cancer cells by infection with lentivirus, then we examined the effects of ICAM-1 on MCF-7 cell metastasis in vitro significantly, and the decreased migration and invasion was accompanied by a reduction of MMP-14. These results implying that ICAM-1 might be involved in the progression of breast cancer metastasis and lentivirus-mediated silencing of ICAM-1 might be a potential therapeutic approach for the treatment of breast cancer.

Introduction

Breast cancer is the most common cancer in women both in developed or less developed world and is estimated that over 508,000 women die due to it each year according to WHO statistics (Global Health Estimates, WHO 2013) (1,2), breast cancer is recognized as the fifth most frequent cause of cancer-associated mortality in women worldwide (3). With advances in treatment of breast cancer such as cytotoxic chemotherapy, antihormonal therapy or radiation therapy, the outcomes of patients have improved significantly in recent years. However, recurrent metastatic breast cancer is still incurable and only 3% of patients with metastatic disease achieve a complete response for >5 years (4). Metastatic breast cancer is a complicated and multi-step malignant tumor involving a biological process that has many stages, and steps, and multiple genes and 90% of cancer-associated deaths are related to cancer cells metastasis. Growing evidence has demonstrated that the change of intercellular adhesion molecule play an important role in the metastasis of breast cancer (5).

Intercellular adhesion molecule-1 (ICAM-1) is a cell surface glycoprotein belonging to immunoglobulin superfamily widely expressed on leukocytes, fibroblasts, keratinocytes, endothelial or epithelial cells and can be upregulated in response to various of inflammatory mediators (6). Previous studies have shown that ICAM-1 plays an important role in tumor cell adhesion, and metastasis progression (7). However, the exact role of ICAM-1 during the process of breast cancer is not well known and there are various reports on whether ICAM-1 can facilitate breast cancer progression. Some argue that ICAM-1 is low expressed in breast cancer tissues than that of benign breast cells or normal breast tissues and in this way escape the lysis by CTLs or NK cells, but others argue that ICAM-1 was overexpressed in breast cancer and promoted the development of tumors (8,9). In previous work carried out on the BCSC-1 gene (breast cancer candidate inhibiting protein 1) it was regarded as a melanoma tumor suppressor (10,11), we found that the migration and invasion ability of breast cancer cell were reduced significantly after transfected with the BCSC-1 gene, then we found that ICAM-1 was affected most significantly by qRT-PCR method. However, the exact role of ICAM-1 in breast cancer remains unclear and further investigation is required to understand the role and molecular mechanisms of ICAM-1 in breast cancer. To this end, we first stably silenced ICAM-1 expression in the breast cancer MCF-7 cells by infection with lentivirus, then we examined the effects of ICAM-1 on MCF-7 cell metastasis in vitro. Previous research has indicated that MMP-14 which belong to the gelatinase MMP subfamily was overexpressed on different tumor cell surfaces including breast cancer and has a critical role for tumor invasion or metastasis (12,13), so the changes of MMP-14 in MCF-7 cells after infected by ICAM-1 lentivirus was also assessed in this study.
Materials and methods

Cells and cell culture. Human breast cancer cells MCF-7 and human embryonic kidney HEK293T cells were cultured in DMEM (Invitrogen, Carlsbad, CA, USA) media containing 10% fetal bovine serum (FBS) (Gibco), 100 IU/ml penicillin and 100 µg/ml streptomycin. All cells were kept at 37˚C and in 5% carbon dioxide humidified atmosphere.

Tissue microarrays and clinical tissue specimens for immunohistochemistry. Tissue microarray contain 69 cases of breast cancer tissues and 3 cases of normal breast tissues was purchased from Alenabio Co. (Xi’an, China). For further confirmation, we also gathered 35 cases of pathologically and clinically confirmed breast cancer from breast surgery centre of Weifang People’s Hospital. The breast cancer tissues and adjacent non-tumor tissues were obtained before the patients received any treatment. All patients above were required to sign an informed consent and our experiments were approved by the institutional ethics committee. The SP immunohistochemical staining was performed according to the manufacturer's instructions (Bioss, Beijing, China). Briefly, tissue microarray of breast cancer was put into citrate buffer (pH 6.0) at 100˚C for 30 min for antigen retrieved, sequential incubations with mouse anti-human ICAM-1 antibody (Cell Signaling Technology, Inc., Danvers, MA, USA) at 1:500 dilution, secondary antibody and finally chromogenic DAB substrate (ZSGB-BIO, Beijing, China). The degree of immunostaining of the tissue microarray was viewed and scored separately by three independent investigators. Cytoplasmic and membranous staining intensity were categorized as: absent staining, 0; weak, 1; moderate, 2; and strong, 3. The percentage of positive stained cells were categorized as: no staining, 0; 0-24%, 1; 25-49%, 2; 50-74%, 3; and 75-100%, 4. The total score was calculated by multiplying the staining intensity and percentage of positive stained cells. The final score ≤2 was negative (-); 3-4 was weak (+); 6-8 was moderate (++); and 9-12 was strong (+++).

Construction of ICAM-1 shRNA lentivirus and MCF-7 cell infection. Three shRNA sequences targeting human ICAM-1 and a negative control sequence (Table I) were designed and cloned into the pLKO.1-SP6-PGK-GFP vector. For lentivirus packaging, HEK293T cells were transfected with ICAM-1 shRNA or control shRNA together with two helper plasmids (psPAX2 and pMD2.G) using Lipofectamine™ 2000 (Invitrogen) according to the manufacturer's instructions. Four days after transfection, the supernatant of HEK293T cells that containing packaged lentivirus was collected and passed through 0.45-µm filters. To infect MCF-7 cells, lentivirus particles were added to the culture medium at a multiplicity of infection (MOI) of 5. The efficiency of infection was determined by GFP percentage by flow cytometry (BD FACSCalibur; BD Biosciences, Baltimore, MD, USA) four days after lentivirus infection.

RNA extraction and quantitative real-time PCR (qRT-PCR). Total RNA of MCF-7 cells were extracted with TRIzol solution (Takara Bio, Inc., Otsu, Japan) at 24 h after infection and reverse transcribed to cDNA using a PrimerScript RT reagent kit (Takara Bio, Inc.) by the manufacturer's instructions. β-actin was used as a normalization control. Primers were chemically synthesized by BioSune Biotechnology (Jinan, China). All primer pairs used for Real-time PCR were designed according to the sequences from GenBank (Table II). Real-time PCR was performed using SYBR Premix Ex Taq (Takara Bio, Inc.) on a CFX96 real-time PCR detection system (Bio-Rad, Berkeley, CA, USA). The PCR conditions were as follows: predegeneration at 94˚C for 1 min, then 35 cycles of denaturation at 94˚C for 30 sec, renaturation at 55˚C for 30 sec, extension at 72˚C for 45 sec. The relative mRNA expression level was determined by cycle threshold (Ct) normalized with
β-actin using the 2-ΔΔCt formula. (CT, cycle threshold) where ΔCT = CT (target gene) - CT (β-actin).

Sequences of sense and antisense primers used for qRT-PCR were as follows: ICAM-1-forward: 5'-ATGCCCA GACATCTGTGTCC-3', ICAM-1-reverse: 5'-GGGGTCT CTATGCCCAACAA-3'; β-actin-forward: 5'-CCTAGCA GCCATTGGCGGTTGG-3', β-actin-reverse: 5'-GAGCTACG AGCTGCTTGACG-3'.

Western blot analysis. Four days after lentivirus infection, MCF-7 cells were washed by PBS and harvested, the protein concentration of each group were determined using BCA assay kit (Beyotime Institute of Biotechnology, Haimen, China). Subsequently, 40 µg protein per lane was separated by 10% SDS-PAGE gel and transferred to NC membranes. The NC membranes (Beyotime Institute of Biotechnology) were blocked by 5% skim milk for 1 h and incubated with primary antibodies to ICAM-1 (Signaling Technology, Inc., 1:1000), MMP-14 (Abcam, Cambridge, MA, USA, 1:1000) and β-actin (Beyotime Institute of Biotechnology, 1:500) overnight, then incubated with their respective secondary antibody for 2 h. All NC membranes were detected by chemiluminescence (ECL, Sangon Biotech, Shanghai, China) for 5 min and exposed to X-ray film for 5-10 min.

Wound-healing assay. For wound-healing assay, MCF-7 cells were plated into 6-well plates at a density of 1x10^5/ml and grown to form a confluent monolayer, wounds were made with sterile pipette tips and photographs of the wounds were taken at indicated time points (0, 24 and 48 h).

Cell migration and invasion assay. MCF-7 cells (5x10^5) were plated in 300 µl of serum-free medium and placed into cell chambers (8-µm pore size, Corning) coated with (Invasion) or without (migration) Matrigel (BD Biosciences), then incubated for 24 h. Cells in the upper filters (inside the chambers) were removed by a sterile swab, the migrated or invaded cells in the lower filters (outside the chambers) were fixed by methanol for 2 h, and stained with crystal violet. The number of migrated or invaded cells in five random optical fields were counted under a microscope.

Colony formation assay. Four days after lentivirus infection, 300 MCF-7 cells of Lv-sh3 group and NS group were seeded into different wells of 6-well plates, respectively, and cultured at 37°C in an incubator for ~14 days until most single colonies had >50 cells. All the colonies were washed by PBS and fixed with 4% methanol, then stained by Giemsa. Images were captured by light microscopy.

Statistical analysis. All the above experiments were performed three times (biological replicates), data are presented as mean ± standard deviation (mean ± SD) and analyzed by SPSS 10.0 software. χ^2 test or Student's t test were applied for statistical analysis and P-value <0.05 was considered as statistical significant in all cases.

Results

ICAM-1 is highly expressed in breast cancer. Previous studies indicated that the expression of ICAM-1 is involved in several carcinomas (6,14,15). To investigate the function of ICAM-1 in breast cancer, we evaluated the expression of ICAM-1 in breast cancer tissue microarrays and clinical tissue specimens using immunohistochemical staining. Of the 104 breast cancer samples, 6 (5.77%) were negative, 26 (25%) were weakly positive, 30 (28.85%) were moderately positive and 42 (40.38%) were strongly positive. In normal breast tissue samples or adja-
cent non-tumor tissues, the results were: 18 (47.37%) negative, 11 (28.94%) weakly positive, 6 (15.79%) moderately positive and 3 (7.89) strongly positive. The ICAM-1 expression level in breast cancer was significantly higher than the normal breast tissue or adjacent non-tumor tissues. These results suggest that ICAM-1 is highly expressed in breast cancer and might be involved in the pathogenesis of breast cancers (Fig. 1 and Table II).

**ICAM-1 lentivirus infection of MCF-7 cells and the efficiency.** To investigate the function of ICAM-1 in breast cancer cells, we used lentivirus-mediated RNAi technology, a powerful method which can knock down the endogenous ICAM-1 gene expression. Four days after lentivirus infection, MCF-7 cells were collected to calculate the number of fluorescent-positive cells by the FACS Calibur Flow Cytometry System. Fluorescence of GFP showed a high percentage of cells being infected by lentivirus (Fig. 2A) and results of FCM indicated the infection efficiency was ~80% (Fig. 2B).

**Lentivirus-mediated RNAi knockdown of ICAM-1 expression in MCF-7 cells.** Four days after lentivirus infection, MCF-7 cells were harvested and the mRNA or protein level were detected by real-time PCR or western blotting method. Real-time PCR results indicated that the ICAM-1 mRNA level of MCF-7 cells in Lv-sh3 group were significantly reduced compared with Lv-shNC group (Fig. 3A, P < 0.05 or P < 0.01), Western blotting confirmed the silencing of ICAM-1 in MCF-7 cells (Fig. 3B and C, P < 0.05). These results suggest that the Lv-sh3 constructed efficiently and specifically knocked down expression of ICAM-1 in MCF-7 cells.

**Suppression of ICAM-1 inhibits the ability of MCF-7 cell metastasis in vitro.** To clarify the relationship between

![Figure 2. ICAM-1 lentivirus infection of MCF-7 cells and the efficiency. MCF-7 cells infected by ICAM-1 lentivirus. We examined the cells that emitting bright fluorescent green under a fluorescent microscope (A). To determine the exact infection efficiency of the lentivirus, we calculated the cell number that can fluoresce under flow cytometry (B).](image-url)
ICAM-1 and the metastatic capability of MCF-7 cells, we stably suppressed ICAM-1 expression using lentivirus mediated RNAi technology. Suppression of ICAM-1 can inhibits metastasis ability of MCF-7 cells in vitro. In the migration test, on average 288.67 ± 53.15 cells in Lv-sh3 group migrated to the lower chamber, whereas 466.67 ± 50.33 cells in Lv-shNC group. In invasion test, there was on average 36 ± 10.53 cells in Lv-sh3 group and 67.67 ± 7.5 in Lv-shNC group. The cell numbers of Lv-sh3 group that migrated through the membrane in migration or invasion test were significantly less than that of Lv-shNC group (Fig. 4 A-C, P < 0.05). In wound-healing assay, the average migration distance in Lv-sh3 group was 90 ± 5 µm (24 h) and 78.33 ± 7.63 µm (48 h), significantly shorter than Lv-shNC group which migrated 131 ± 6.55 µm (24 h) and 105 ± 5 µm (48 h), respectively (Fig. 4D and E, P < 0.05).

**ICAM-1 gene silencing affects MMP-14 protein expression levels in MCF-7 cells.** Matrix metalloproteinase (MMPs) are critical factors involved in tumor metastasis and we detected the influence of ICAM-1 gene silencing on MMP-14 protein expression levels by western blot analysis. As revealed in Fig. 5, we found that gene silencing of ICAM-1 can caused apparent decrease in MMP-14 expression levels, indicating that ICAM-1 mediated breast cancer cell metastasis might be linked with matrix metalloproteinase (MMP-14) (Fig. 5A and B, P < 0.05).

**ICAM-1 silencing reduces the colony formation ability of MCF-7 cells.** Giemsa staining showed that the colony number in Lv-sh3 group was 58 ± 7.94 and significantly less than that in Lv-shNC group (87.33 ± 8.74). Moreover, the size of the colony in Lv-sh3 group was reduced markedly compared with Lv-shNC group, indicating that ICAM-1 gene silencing could inhibit the colony formation ability of MCF-7 cells in vitro (Fig. 6A and B, P < 0.05).

**Discussion**

Tumor invasion or metastasis are major factors causing death of patients and majority of cancer patients succumb to the complications from distant metastases. Growing evidence has demonstrated that adhesion molecules expressed on tumor cell surface can mediate the adhesion between tumor cells and stromal or vascular endothelial cells and play an important role in the occurrence and development of tumors (16).

ICAM-1 is a cell surface glycoprotein that belongs to immunoglobulin superfamily, and expressed in a wide variety of lymphocytes or tumor cells. The ligand of ICAM-1 is lymphocyte function associated antigen 1 (LFA-1) and the interaction between ICAM-1 and its ligand can promote tumor metastasis through modulating cell-cell adhesion (17). However, the exact role of and function of ICAM-1 in the development of tumors has not been fully elucidated. It has been reported that the upregulation of ICAM-1 expression can increase the invasion and metastasis ability of tumor cells by promoting the adhesion between tumor cells and vascular endothelial or lymphatic endothelial cells, ultimately resulting in the distant metastasis of tumor cells (18). ICAM-1 is highly expressed in different human malignancies and believed to be involved in their pathogenesis. Previous research has shown that upregulation of ICAM-1 has been demonstrated in different malignant tumors including liver cancer, esophageal cancer, renal cell carcinoma, squamous carcinoma, gastric cancer or pancreatic cancer and associated with poor prognosis (14,15,19-22), Under inflammatory environment, TGF (transforming growth factor) promoted osteosarcoma cell metastasis through the increasement of ICAM-1 by Akt signal pathway (23). Downregulation of ICAM-1 by short hairpin RNA (shRNA) transduction methods mitigated mouse colon cancer cell MC38 invasion ability (24). Proto ongenc K-ras could increase ICAM-1 expression in pancreatic acinar cells and the formation of precancerous lesions (25). ICAM-1 was found to be expressed at high levels in tumor-associated endothelium or tumor cells and was associated with epithelial carcinogenesis (26). Blocking NF-κB pathway by Bay11-7082 can downregulate ICAM-1 expression and inhibit the disintegration of the lymph-endothelial barrier triggered by MCF-7 cells (27). However, data from other experiments regard that high expression of ICAM-1 enhances the anti-tumor ability through mediating the adhesion between tumor cells and cytotoxic T cells or NK cells (28), low expression of ICAM-1 allowing tumors to escape immune recognition (9). Breast cancer tissue or breast cancer cell lines showed low expression of ICAM-1 than that of normal breast epithelium or benign breast cells, the overexpression of ICAM-1 after TNF stimulation was able to help lymphokine-stimulated killer
Di et al.: Downregulation of Human ICAM-1 Attenuates Metastasis

The expression of ICAM-1 can be regulated by transcription factor E2F1 in prostate cells through NF-κB signaling pathway, silencing of E2F1 can increase ICAM-1 mediated leucocyte infiltration and inhibits tumor growth (30). Other substances such as cannabidiol (CBD) elicits upregulation of ICAM-1 and inhibits lung cancer cell line A549, H358 or H460 metastasis, as an intermediate link in the CBD antimetastatic action on human lung cancer cells. ICAM-1 can increase cancer cell susceptibility to LAK cell-mediated cytol-
ICAM-1 silencing reduces the colony formation ability of MCF-7 cells. The number and the size of the colonies of MCF-7 cells in Lv-sh3 group compared with that in Lv-shNC group (A and B). *P<0.05 compared with Lv-shNC group.

Figure 6.


